P1/2, N=300, Active, not recruiting, Australasian Leukaemia & Lymphoma Group | Recruiting --> Active, not recruiting

The safety profile of upadacitinib remained consistent with previous analyses, with no new safety concerns through 7 years. Upadacitinib and adalimumab (continuous or rescue treatment) maintained disease activity targets throughout the 7-year treatment period. Upadacitinib exhibited an acceptable benefit-risk profile for long-term RA treatment.

P2, N=108, Not yet recruiting, Yale University | Trial completion date: Aug 2029 --> Jun 2030 | Trial primary completion date: Aug 2029 --> Jan 2029

P=N/A, N=14, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Apr 2026 --> Sep 2026

P=N/A, N=23900, Not yet recruiting, Takeda | Trial completion date: Dec 2025 --> Dec 2026 | Initiation date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=150, Not yet recruiting, Nantes University Hospital | Trial completion date: Oct 2027 --> Apr 2031 | Trial primary completion date: Oct 2027 --> Apr 2030

P4, N=30, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Although these findings required an urgent repeat marrow evaluation, cytogenetic/molecular testing, and hematology clearance due to the high risk of an indeterminate or pre-leukemic state, the presence of active, refractory gastrointestinal bleeding prompted the immediate initiation of infliximab induction...Severe systemic inflammation can create a reactive bone marrow phenotype indistinguishable from early myeloid neoplasia or myelodysplastic syndrome, posing a life-threatening diagnostic trap. Comprehensive hematologic evaluation-including repeat bone marrow assessment under controlled inflammatory conditions-should be considered mandatory before initiating biologic therapy in patients with CD and unexplained cytopenias or borderline blast counts.

All patients received nonsteroidal anti-inflammatory drugs as initial therapy, and one required additional treatment with oral methotrexate and adalimumab. Serum cytokine analysis was performed in three cases, revealing elevated levels of both pro- and anti-inflammatory cytokines, such as interleukin (IL)-6, IL-10, and IL-33 in the pre-treatment state. These cases underscore the clinical heterogeneity of CNO/CRMO.

In multivariate analysis, receiving an alkylator based induction, radiation therapy, achieving a complete response after auto-SCT, use of cyclophosphamide for stem cell mobilization and lenalidomide maintenance were independent predictors of developing SHM. Patients with MM who developed a SHM had an inferior overall survival (OS). Given the median OS for MM continues to improve, monitoring for SHM and risk mitigation strategies is crucial.

However, various factors can lead to failure in hematopoietic stem cell mobilization in some patients, including age, type of malignancy, chemotherapy regimens (such as fludarabine, Melphalan, and Lenalidomide), radiotherapy, bone marrow cellularity, and comorbidities. It is crucial to recognize that diabetes can significantly affect the outcomes of hematopoietic stem cell transplantation. Factors such as poor stem cell mobilization, prolonged engraftment times, and increased need for blood product transfusions underscore the importance of considering diabetes in HSCT candidates.

P4, N=50, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.